Nuvigil is owned by Cephalon.
Nuvigil contains Armodafinil.
Nuvigil has a total of 4 drug patents out of which 0 drug patents have expired.
Nuvigil was authorised for market use on 15 June, 2007.
Nuvigil is available in tablet;oral dosage forms.
The generics of Nuvigil are possible to be released after 18 June, 2024.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7132570||CEPHALON||Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil|| |
(6 months from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7297346||CEPHALON||Pharmaceutical formulations of modafinil|| |
(5 months from now)
|CEPHALON||Pharmaceutical formulations of modafinil|| |
(11 months from now)
|CEPHALON||Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil|| |
(1 year, 10 days from now)
Drugs and Companies using ARMODAFINIL ingredient
Market Authorisation Date: 15 June, 2007
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic